Kymera Therapeutics (KYMR) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KYMR shares.
View KYMR analyst ratings or view top-rated stocks.

9 equities research analysts have issued 1-year price objectives for Kymera Therapeutics' stock. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they predict the company's stock price to reach $48.10 in the next year. This suggests a possible upside of 236.4% from the stock's current price.
View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts.

Kymera Therapeutics' stock was trading at $24.96 at the start of the year. Since then, KYMR stock has decreased by 42.7% and is now trading at $14.30.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KYMR earnings forecast.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.03. The business earned $16.51 million during the quarter, compared to the consensus estimate of $13.93 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 33.17% and a negative net margin of 305.01%. The firm's revenue for the quarter was up 43.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.78) earnings per share.

ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Simplify Propel Opportunities ETF (SURI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

(KYMR) raised $126 million in an initial public offering (IPO) on Friday, August 21st 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."

Kymera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.82%), State Street Corp (4.73%), Rock Springs Capital Management LP (2.68%), Wasatch Advisors LP (2.16%), Dimensional Fund Advisors LP (1.52%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends.

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KYMR stock can currently be purchased for approximately $14.30.

Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $792.36 million and generates $46.83 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.

The company employs 181 workers across the globe.

Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com.